Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia

1  Introduction

Chronic myeloid leukemia (CML) is a hematopoietic malignancy originating from hematopoietic stem cells, with an annual incidence of 1–2 per 100,000 people, accounting for 15% of all leukemia cases [1]. In Western countries, the median age at diagnosis is approximately 65 years, whereas in Asia and Africa, it is less than 50 years [2,3]. CML is characterized by the Philadelphia chromosome, which results from a reciprocal translocation between chromosomes 9 and 22. This chromosome produces the breakpoint cluster region::Abelson murine leukemia 1 (BCR::ABL1) fusion gene. The BCR::ABL1 protein transcribed from this gene possesses constitutive tyrosine kinase activity, which causes CML development. Therefore, BCR::ABL1 is a therapeutic target for CML and serves as a critical factor in its diagnosis and monitoring [4].

Imatinib, the first BCR::ABL1 tyrosine kinase inhibitor (TKI) introduced in the early 2000s, dramatically improved the 5-year and 10-year survival rates compared to conventional interferon or chemotherapy [5–7]. However, despite these therapeutic advances, approximately 20%–30% of patients treated with first-line therapy (first-generation TKI imatinib and second-generation TKIs nilotinib, dasatinib, and bosutinib) develop BCR::ABL1 TKI resistance [3]. BCR::ABL1 TKI resistance mechanisms are broadly categorized into BCR::ABL1-dependent pathways caused by ABL1 gene mutations or overexpression, and BCR::ABL1-independent pathways (activation of bypass pathways, changes in B-cell/CLL lymphoma 2 (Bcl-2) family protein expression, tumor suppressors, microRNAs (miRNAs), and molecular chaperones) [8].

2  BCR::ABL1-Dependent Resistance Mechanism

2.1 BCR::ABL1 Gene Mutation

The factors contributing to BCR::ABL1-dependent resistance are mainly attributed to mutations in the BCR::ABL1 gene (Fig. 1). These mutations reduce the efficacy of TKIs by interfering with their binding. Currently, over 100 mutation sites have been identified and susceptibility to TKIs varies depending on the mutation site [9,10]. Representative examples include T315I, a mutation in the binding site of first- and second-generation TKIs; E255K/V and Y253F/H, in the ATP-binding domain; and F359V and M351T, in the catalytic domain [10,11]. Y253F/H, E255K/V, T315I, M351T, and F359V confer resistance to imatinib; whereas Y253H, E255K/V, T315I, and F359V confer resistance to nilotinib; E255K/V and T315I confer resistance to bosutinib; and T315I confers resistance to dasatinib [12–15]. For T315I, ponatinib or asciminib, which bind to the myristoyl pocket of ABL1 and allosterically inhibit BCR::ABL1, were used. The emergence of double mutations, including T315I (T315I/G250E, T315I/E255K, T315I/E255V, and E255V/Y253H) for ponatinib, has been shown to be involved in resistance in vitro [16–18]. Furthermore, the dual mutations T315I/E255K has been reported in ponatinib-resistant cases [19,20]. Moreover, V468F, P465S, C464W, F359C/I/V, and A337V are known resistance mutations to asciminib, and V468F, P465S, C464W, and F359I have been identified in clinical cases [21]. As shown in Fig. 1, individual BCR::ABL1 mutations exhibited different susceptibility profiles to various TKIs, necessitating a switch to the TKI corresponding to the mutation. Furthermore, the emergence of genetic mutations other than BCR::ABL1 and chromosomal abnormalities in Ph-positive cells have also been shown to be involved in TKI resistance [22–26]. Therefore, analysis of genetic mutations, not restricted to BCR::ABL1, is crucial for treatment management in CML.

Figure 1: Major ABL1 gene mutations observed in patients with CML and their susceptibility to TKIs. The table in the figure indicates sensitivity, moderate resistance, and high resistance based on the IC50 values for cell proliferation of TKIs in ABL1 mutant cells. The figure shows the location of the ABL1 mutation [10–21]. ABL1: abelson murine leukemia 1; CML: chronic myeloid leukemia; TKIs: tyrosine kinase inhibitors; IC50: 50% inhibition concentration; BCR: breakpoint cluster region

Next-generation sequencing (NGS) has identified ABL1 mutations associated with TKI resistance, as shown in Fig. 1, and genomic abnormalities in genes such as NMT2A, RUNX1, ASXL1, and IKZF1. These genomic abnormalities have been shown to potentially cause drug resistance in CML [27–30]. Furthermore, approximately 15% to 25% of patients exhibit genomic abnormalities other than BCR::ABL1 at CML diagnosis, and these abnormalities have been shown to be associated with TKI failure [28,29]. Moreover, patients with chronic-phase CML who have failed treatment with at least two different TKIs frequently harbor additional oncogenic mutations beyond BCR::ABL1, and that the number of these mutations correlates with an increased risk of TKI treatment failure [31]. Therefore, TKI sensitivity in BCR::ABL1 mutations may be altered by other oncogene mutations. Digital droplet polymerase chain reaction (ddPCR) is a highly sensitive method capable of detecting BCR::ABL1 transcripts, surpassing conventional qualitative PCR. ddPCR exhibits superior specificity and sensitivity compared to NGS in patients with TKI-resistant CML already identified as harboring ABL1 mutations via NGS analysis [32]. Additionally, ddPCR has been shown to detect T315I mutation with high sensitivity in patients with CML [33]. Based on these findings, genomic analysis using NGS and ddPCR may play a crucial role in the management of TKI treatment.

2.2 BCR::ABL1 Overexpression

BCR-ABL1 overexpression is a factor in the BCR::ABL1-dependent mechanism of imatinib resistance. However, its frequency is low compared to that of BCR::ABL1 gene mutations, and its significance is low (only two out of 66 imatinib-resistant patients) [34]. Nevertheless, CML cells with high BCR::ABL1 expression exhibited reduced imatinib sensitivity and may promote the emergence of mutant clones compared to low-expression cells. Furthermore, CML cells in the blast crisis phase show higher BCR::ABL1 expression than those in the chronic phase, resulting in lower imatinib sensitivity [34].

3  BCR::ABL1-Independent Resistance Mechanisms

The major cause of resistance to BCR::ABL1 TKIs therapy is mutation; however, approximately 40%–50% of cases of resistance to BCR::ABL1 TKIs therapy arise via independent pathways [35,36]. Therefore, elucidating the factors involved in independent pathways may improve the prognosis of patients with drug resistance.

3.1 Bypass Pathway

TKI resistance due to the activation of bypass pathways is frequently observed not only in BCR::ABL1 TKIs, but also in other TKI resistance mechanisms [37–40]. BCR::ABL1 TKIs inhibit ABL1 tyrosine kinase activity and induce apoptosis in CML cells by inhibiting the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK), phosphoinositide 3-kinase (PI3K)/Akt, and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways. However, some cells survive by activating these signals through other pathways (Fig. 2). Activation of the MEK/ERK pathway via tumor progression locus 2 (TPL2) overexpression (mitogen-activated protein kinase kinase kinase (MAPKKK)) or the receptor tyrosine kinase MET has been shown to induce imatinib and dasatinib resistance [41–45]. Furthermore, activation of the PI3K/Akt/mammalian target of rapamycin (mTOR) pathway is involved in the acquisition of imatinib resistance in vitro and has been observed in patients with imatinib resistance [46]. Moreover, interleukin 7 expressed by bone marrow stromal cells activates JAK/STAT5 in CML cells; STAT3 is activated by the addition of bone marrow stromal cell culture supernatant, and STAT3 activation is observed in patients with imatinib resistance [47–49]. In addition, FLT3, a receptor tyrosine kinase, is activated in approximately half of the acute-phase CML cases and contributes to resistance to BCR::ABL1 TKIs [50]. Activation of the bone morphogenetic pathway receptor (BMPR)/ALK pathway has also been shown to contribute to BCR::ABL1 TKI resistance [51,52]. Thus, various factors contribute to BCR::ABL1 TKI resistance through the activation of bypass pathways, suggesting that treatment targets may be diverse. Consequently, identifying factors that serve as therapeutic targets for each patient using approaches such as NGS-based gene mutation analysis and RNA sequencing is necessary.

Figure 2: Schematic representation of BCR::ABL1-independent mechanisms via bypass pathways. Activation of downstream signaling pathways (PI3K/AKT, JAK/STAT, and RAS/MAPK) through increased growth factors and cytokines and activation of signaling molecules (receptor tyrosine kinase and TPL2 (MAPKKK)) [41–49]. HGF: hepatocyte growth factor; IL-7: interleukin 7; IL-7R: IL-7 receptor; TPL2: tumor progression locus 2; Raf: rapidly accelerated fibrosarcoma; MEK1/2: mitogen-activated protein kinase kinase 1/2; PI3K: phosphoinositide 3-kinase; JAK2: Janus kinase 2; STAT3: signal transducer and activator of transcription 3; STAT5: signal transducer and activator of transcription 5; BCR: breakpoint cluster region; ABL1: abelson murine leukemia 1; TKI: tyrosine kinase inhibitor

3.2 Changes in Bcl-2 Family Protein Expression

Bcl-2 family proteins are broadly categorized into apoptosis inhibitors (Bcl-2, B-cell lymphoma extra large (Bcl-xL), Myeloid cell leukemia 1 (Mcl-1)) and apoptosis promoters (Bcl-2-associated X protein (Bax), Bcl-2 interacting mediator of cell death (Bim), Noxa, p53 upregulated modulator of apoptosis (Puma), BCL2 associated agonist of cell death (Bad)) (Fig. 3A). Bcl-2 and other proteins regulate Bax function by binding to it [53]. CML patients with BIM deletion gene polymorphisms show resistance to BCR::ABL1 TKIs. Furthermore, BH-3 mimetic drugs, such as venetoclax, have been suggested to be potentially effective in these patients [54]. Exosomes secreted by mesenchymal stem cells present in the bone microenvironment increase Bcl-2 expression in CML cells, inducing imatinib resistance [55]. Patients with chronic-phase CML exhibiting imatinib resistance, Bcl-2 overexpression and decreased Bad expression are observed in tumor cells [56]. Furthermore, studies using CRISPR-Cas9 knockout screening to investigate TKI resistance factors have identified the involvement of Bax, Bim, Noxa, and Puma, and have also demonstrated that resistance can be overcome by navitoclax and venetoclax [57]. These findings suggest that changes in Bcl-2 family protein expression regulate intrinsic apoptotic pathways and control TKI-induced cell death. Furthermore, gene deletions or amplifications can be evaluated using NGS.

Figure 3: Schematic representation of BCR::ABL1-independent mechanisms mediated by changes in Bcl-2 family, MDM2, p53, and HSP90 expression. (A) Activation of signaling molecules increases the expression of Bcl-2 and Bcl-xL, promoting survival and inducing TKI resistance. Additionally, BIM deletion increases the expression of survival factors, such as Bcl-2 [53–56]. (B) MDM2 induces TKI resistance by suppressing the expression of Bax and other proteins through the degradation of p53. Furthermore, reduced MDM2 expression due to SNPs increases p53 activity, thereby enhancing TKI sensitivity [58–67]. (C) HSP90 induces resistance to TKIs by binding to target proteins (such as signaling molecules), stabilizing them, and inducing their constitutive activation [72–75]. BCR: breakpoint cluster region; ABL1: abelson murine leukemia 1; Bcl-2: B-cell/CLL lymphoma 2; Bcl-xL: B-cell lymphoma extra large; Bax: Bcl-2-associated X protein; Bim: Bcl-2 interacting mediator of cell death; TKI: tyrosine kinase inhibitor; MDM2: mouse double minute protein 2; HSP90: heat shock protein 90; Raf: rapidly accelerated fibrosarcoma; MEK1/2: mitogen-activated protein kinase kinase 1/2; JAK2: Janus kinase 2; STAT3: signal transducer and activator of transcription 3; STAT5: signal transducer and activator of transcription 5

3.3 Altered Expression of Mouse Double Minute Protein 2 (MDM2) and p53

The tumor suppressor gene p53 induced cell death by enhancing the expression of Bax, Puma, Noxa, and others, and suppressed cell proliferation by increasing p21 expression (Fig. 3B). Therefore, disruption of pathways involving this gene promotes cell survival and proliferation [58,59]. Furthermore, p53 loss and factors involved in regulating these tumor suppressor genes are significantly implicated in TKI resistance [60–63].

MDM2 binds to p53, inhibiting its transcriptional activity while also acting as an E3 ubiquitin ligase to promote proteasome-mediated degradation [64]. Furthermore, MDM2 expression increased with CML progression and downregulated p53 expression [65]. BCR::ABL1 increases the expression of p53 and p53 target genes; however, its potent oncogenic effects promote the survival of CML cells [66]. Furthermore, the analysis of BCR::ABL1 TKI efficacy in MDM2 genetic polymorphisms showed that individual MDM2 polymorphisms did not affect TKI sensitivity. However, the MDM2 single nucleotide polymorphism (SNP) 309 G/G genotype alone was associated with reduced major molecular remission achievement and increased risk of moderate/high Sokal scores, suggesting that it may be a poor prognostic factor. Furthermore, MDM2 del1518 polymorphism alone, MDM2 del1518/MDM2 SNP309, or MDM2 SNP309/TP53 SNP215 improved OS in TKI non-responders. Furthermore, TKI non-responders harboring the MDM2 SNP309/TP53 SNP215 polymorphism demonstrated a higher molecular response rate, suggesting that this polymorphism may be a low-risk factor in regulating TKI response [67]. These findings suggest that MDM2 polymorphisms may regulate MDM2 expression, which in turn differentially affects p53 activity and potentially contributes to an improved TKI response.

In addition, MDM2 activation is regulated by PAK6, which contributes to TKI resistance by downregulating p53 and p21 expression [68]. MDM2 regulates p21 expression in a p53-independent manner and suppresses cell proliferation even in p53-null CML cells [68]. While p53 deletion has been reported to be involved in imatinib resistance [69], other studies have found no change in p53 gene expression between BCR::ABL1-responders and non-responders [70]. In CML, genomic instability becomes more likely as the disease progresses, and mutations or deletions in p53 are also known to occur [71]. The absence of changes in p53 expression between TKI responders and non-responders may be due to the exclusion of patients with a blast crisis from the study population [70]. However, if MDM2 regulates p21 expression in a p53-independent manner, MDM2 could be a useful therapeutic target for TKI resistance, regardless of the status of the p53 gene in patients with CML.

3.4 Heat Shock Protein 90

Heat shock proteins (HSPs) are essential for maintaining the correct folding, stability, and activity of intracellular proteins and play a crucial role in cell survival (Fig. 3C). In tumors, including leukemia, they have been reported to be involved in stabilizing survival-promoting signaling factors and apoptosis-inhibiting factors [72]. HSP90 is involved in the progression and pathogenesis of CML, enhancing the stabilization of BCR::ABL1 by binding to it [73,74]. Furthermore, high expression of HSP90 is involved in imatinib resistance in CML. This factor has also been shown to activate downstream signaling molecules in key signaling pathways downstream of BCR::ABL1, such as the JAK/STAT, PI3K/Akt, and Raf/MEK/ERK pathways, by stabilizing them [72,75].

3.5 MicroRNA

MicroRNAs (miRNAs) are non-coding RNA that regulate gene expression by degrading messenger RNA or inhibiting translation. Recently, they have been shown to be involved in the progression of various malignancies, including hematological malignancies. However, miRNAs involved in suppression have also been reported, and oncogenic and tumor-suppressive miRNAs are known [76,77]. In CML, miR-18a-5p high expression is implicated in tumor progression by maintaining JAK2 and phosphorylating STAT3 expression through the downregulation of suppressor of cytokine signaling 5. miR-181a enhances cell proliferation inhibition and imatinib sensitivity by regulating RelA expression, whereas miR-181c expression is lower in resistant patients than in imatinib-sensitive patients. miR-30a and miR-30e expression is downregulated in patients with CML, and their upregulation increases imatinib sensitivity. miR-21 and miR-155 are upregulated in patients with CML and are involved in disease progression and imatinib resistance [78]. While miR-29 has been reported to act as an oncogene in acute myeloid leukemia and contribute to imatinib resistance by regulating ten-eleven translocation (TET) and neurofibromatosis type 1 (NF1) expression, it has also been shown to suppress CML cell proliferation by targeting ABL1 [79–82]. Furthermore, while some reports have indicated that miR-10 expression is elevated in imatinib-resistant cells, others have shown that it is decreased [83–85]. Thus, miRNAs are potential therapeutic targets for CML because of their involvement in tumor progression and suppression. However, a detailed investigation is required to elucidate the roles of certain miRNAs, including the causes of resistance and their impact on leukemia stem cells.

4  Therapeutic Approaches to BCR::ABL1 TKIs Resistance

For treating resistance to BCR::ABL1 TKIs, therapeutic approaches tailored to each cause are crucial. The confirmation of TKI resistance or recurrence is also an important factor in treatment decisions. Essential aspects of CML treatment management include confirming ABL1 mutations via NGS, detecting other cancer gene mutations, and verifying ABL1 gene mutations and BCR::ABL1 transcript levels using ddPCR [27,32,33,86].

4.1 Therapeutic Approaches to Resistance Due to Genetic Mutations

Currently, imatinib, nilotinib, dasatinib, and bosutinib are first-line treatment options in many countries. When resistance mutations arise, ponatinib and asciminib become appropriate options. Asciminib resistance arises from mutations, such as V468F, P465S, C464W, F359C/I/V, and A337V, in the myristoyl pocket of its binding site. In vitro and in vivo analyses suggested that ponatinib monotherapy and the combination of ponatinib and venetoclax might be effective against resistant clones harboring these mutations [87]. Furthermore, based on a case report, dasatinib has been shown to be effective against A337V mutations [88]. Although dual mutations cause ponatinib resistance, the combination of asciminib and ponatinib induces cell death in resistant cells derived from patients with CML and suppress tumor growth in vivo [18]. Furthermore, the combination of ponatinib and asciminib has been reported to be potentially effective against the T315I/E335G double mutation [89]. Furthermore, in clinical trials, the third-generation BCR::ABL1 TKI olverembatinib achieved a complete cytogenetic response in 15 of 26 patients who had received prior ponatinib treatment, and a major molecular response in 11 of 30 patients. Among the patients who received asciminib treatment, four of eight achieved a complete cytogenetic response and four of twelve achieved a major molecular response [90]. Furthermore, clinical trials combining asciminib with imatinib, nilotinib, or dasatinib have attempted to prevent dual mutations and resistance, and favorable results have been reported [91].

Allogeneic hematopoietic stem cell transplantation (HSCT) has become a treatment option for BCR::ABL1 TKIs (particularly in patients who have failed three or more TKIs and/or ponatinib/asciminib) and persistent CML cells with disease progression [92]. The 2020 European Leukemia Network and National Comprehensive Cancer Network guidelines also present HSCT as an effective treatment option for patients with acquired resistance to TKIs (both BCR::ABL1-dependent and independent mechanisms) [3,93]. Seventy patients who underwent HSCT after BCR::ABL1 TKI failure for 20 years had a 5-year overall survival rate of 57.7% (45.1%–68.5%). It also indicated that patients who achieved cytogenetic and molecular remission prior to transplantation had a better prognosis than those who achieved only hematological remission [94]. Furthermore, HSCT performed more than one year after diagnosis increases the risk of non-relapse mortality (NRM) by approximately 52% compared with earlier timing. Moreover, receiving treatment after initiating TKI therapy significantly reduces the risk of NRM by up to 40% compared with treatment before TKI initiation [95]. However, if recurrence occurs after HSCT, treatment primarily involves interferons and chemotherapy, and the prognosis is extremely poor. Therefore, regular long-term monitoring of BCR::ABL1 transcripts is necessary after HSCT [96].

4.2 Therapeutic Approaches to Resistance via Bypass Pathway Activation

Resistance due to bypass pathway activation is difficult to interpret because its causes are diverse; however, it is a major factor in BCR::ABL1-independent resistance. Some clinical trials have been conducted based on the basic research findings. JAK2-mediated STAT3 and STAT5 activation has been shown to confers TKI resistance to CD34-positive CML cells [97]. Therefore, several clinical trials combining JAK inhibitors with TKIs have been conducted. Combination therapy with ruxolitinib and nilotinib demonstrated higher efficacy than nilotinib alone, with no issues regarding tolerability [98]. Furthermore, a Phase 2 trial reported that ruxolitinib plus TKI combination therapy demonstrated high efficacy with no tolerability issues compared with TKI monotherapy [99]. Additional clinical trials (NCT03654768 and NCT03610971) are currently ongoing. Additionally, peroxisome proliferator-activated receptor γ (PPARγ) is known to negatively regulate STAT5 expression, and pioglitazone, a PPARγ agonist, enhances the effect of imatinib by decreasing STAT5 expression [100]. In a clinical trial involving patients who had not achieved molecular response 4.5 (BCR-ABL1/ABL1IS RNA levels ≤ 0.0032%), combination therapy with imatinib and pioglitazone demonstrated a favorable cumulative achievement rate of 56% for molecular response 4.5 over 12 months, compared to 23% with imatinib alone, with no issues regarding tolerability [101].

Basic research has also demonstrated that the mTOR inhibitors rapamycin and everolimus enhance the effects of imatinib, inducing cell death in imatinib-resistant cells [102–104]. Clinical trials (NCT00093639 and NCT00101088) have been conducted in patients with CML; however, the detailed results remain unclear. Targeting mTOR may be effective; however, more effective agents are required. Additionally, basic research has revealed that the activation of the MEK/ERK pathway is also important in BCR::ABL1-independent resistance; however, no clinical trials have been conducted. Moreover, in basic research, the dual inhibitor KF1601, which targets both BCR::ABL1 and FLT3, induces cell death in acute-phase CML cells harboring the BCR::ABL1 T315I mutation and FLT3 activation [105]; combined therapy with ALK TKIs suppressing BMPR/ALK pathway activation and BCR::ABL1 TKIs may also be effective [106]. In the future, agents that inhibit this pathway are expected to serve as therapeutic tools for overcoming resistance.

4.3 Therapeutic Approach Targeting Resistance via Changes in Bcl-2 Family Protein Expression

Bcl-2 has been shown to be highly expressed in cells during the acute phase of CML, and it may contribute to TKI resistance [107]. Combination therapy with nilotinib and venetoclax in CD34-positive cells isolated from patients with CML has been shown to enhance apoptosis induction compared to monotherapy with either agent [108]. Furthermore, the combination of nilotinib and venetoclax induces significantly more apoptosis in CML cells collected from patients with acute-phase CML than in bone marrow cells collected from healthy donors [109]. Moreover, the combination of ponatinib and venetoclax has been shown to suppress tumor growth and prolong survival in vivo in the asciminib-resistant CML cell line KCL-22 [87]. The efficacy of BCR::ABL1 TKIs + venetoclax combination therapy has been evaluated in patients with acute-phase CML, with a reported response rate of 75% [110]. Furthermore, clinical trials (NCT02689440 and NCT04188405) are currently underway to evaluate combination therapy with dasatinib and venetoclax in patients with early chronic-phase CML and combination therapy with decitabine, venetoclax, and ponatinib in patients with acute- or accelerated-phase CML, with anticipated promising results.

4.4 Therapeutic Approaches Targeting Resistance via MDM2 and p53 Expression Changes

Stabilization of p53 by MDM2 inhibitors, such as Nutlin-3 and MI-219, enhances imatinib sensitivity in CML cells with or without BCR::ABL1 mutations by increasing the expression of p53 target genes, thereby inducing apoptosis [111,112]. Furthermore, p53 activation via MDM2 inhibition eliminates the pluripotency of CML stem cells and potentially overcomes BCR::ABL1 TKI resistance [113]. MDM2 inhibitors are ineffective in treating TP53-mutated malignancies. Clinical trials have evaluated the efficacy of KRT-232 in combination with either nilotinib or dasatinib in patients with p53 wild-type chronic-phase or accelerated-phase CML who are resistant or refractory to at least one BCR::ABL1 TKI (NCT04835584).

4.5 Therapeutic Approach Targeting Resistance via HSP90

Inhibition of HSP90 induces degradation through destabilization of BCR::ABL1 and downstream signaling factors, such as Raf-1 and Akt, making it a promising therapeutic approach for both BCR::ABL1-dependent and independent resistance. In vivo studies have demonstrated that HSP90 inhibition suppresses tumor growth and prolongs survival in T315I-positive CML cells, while also reducing the number of CML stem cells [114]. Furthermore, the HSP90 inhibitor NVP-AUY922 induces cell death in cells harboring various ABL1 mutations responsible for BCR::ABL1 inhibitor resistance when combined with imatinib or nilotinib [115]. Moreover, HSP90 inhibitors have been reported to be effective against imatinib resistance caused by the activation of bypass pathways such as Met receptor tyrosine kinase activation [74]. Currently, the only approved HSP90 inhibitor is pimitespib; however, this drug is indicated for gastrointestinal stromal tumors and cannot be used for CML treatment. Gamitrinib has been studied for advanced cancer (NCT04827810), ganetespib for hormone receptor-positive breast cancer (NCT01560416), and XL888 in combination with vemurafenib and cobimetinib for BRAF-mutated melanoma (NCT02721459). If these clinical trials yield useful results, they could expand the treatment options and potentially be applied to CML therapy.

4.6 Therapeutic Approach to Resistance via miRNA

CML stem cells from patients with chronic-phase CML show universally reduced miRNA levels compared to hematopoietic stem cells from healthy donors, suggesting their involvement in CML progression, treatment responsiveness, and TKI resistance [116,117]. Furthermore, miRNAs such as miR-30 and miR-185 are involved in the degradation of BCR::ABL1 mRNA in TKI-resistant cells, suggesting their potential as therapeutic targets for overcoming drug resistance [117]. However, while miR-29 suppresses CML cell proliferation by targeting ABL1, acting as a therapeutic and favorable prognostic factor, it also acts as an oncogene in acute myeloid leukemia by regulating TET expression, contributing to proliferation and imatinib resistance by regulating NF1 expression [79–82]. Furthermore, while some reports indicate that miR-10 is downregulated in imatinib resistance and is involved in proliferation suppression, others suggest that its upregulation contributes to imatinib insensitivity [83–85]. Although miRNAs have great potential for elucidating disease mechanisms and as therapeutic tools, further research is essential to translate these findings into effective treatment strategies.

5  Conclusion

Recent studies have elucidated key cellular and molecular pathways in CML and have presented novel therapeutic strategies for targeting these pathways. Although TKIs have significantly advanced CML treatment, resistance and insensitivity remain as challenges, making the exploration of approaches to overcome these critical issues. Novel approaches, including those involving miRNAs, have the potential to improve TKI sensitivity, overcome resistance, and preventing resistance development. A comprehensive multitarget strategy is essential to address the complexity of CML progression and resistance. The evolving landscape of CML treatment relies on research by many scientists, driving the discovery of innovative strategies, including mechanisms to circumvent BCR::ABL-independent resistance. Although many of these approaches remain experimental, further research and clinical validation are crucial for translating these findings into effective treatment options.

Acknowledgement: Not applicable.

Funding Statement: This work was supported in part by a Grant-in-Aid for Scientific Research (C) (Grant numbers 25K10102) from the Japan Society for the Promotion of Science (JSPS).

Author Contributions: The authors confirm contribution to the paper as follows: conceptualization, Masanobu Tsubaki; writing—original draft preparation, Masanobu Tsubaki; writing—review and editing, Masanobu Tsubaki, Taira Matsuo and Rie Komori; visualization, Masanobu Tsubaki, Taira Matsuo and Rie Komori; funding acquisition, Masanobu Tsubaki. All authors reviewed the results and approved the final version of the manuscript.

Availability of Data and Materials: Not applicable.

Ethics Approval: Not applicable.

Conflicts of Interest: The authors declare no conflicts of interest to report regarding the present study.

Abbreviations

References

1. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022;97(9):1236–56. doi:10.1002/ajh.26642. [Google Scholar] [PubMed] [CrossRef]

2. Chaulagain P, Poudel A, Aryal S, Sainatham C, Lutfi F. Global trends of burden of chronic myeloid leukemia based on socio-demographic index (SDIa comparative epidemiological study. Blood. 2024;144(Suppl 1):7918. doi:10.1182/blood-2024-210443. [Google Scholar] [CrossRef]

3. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84. doi:10.1038/s41375-020-0776-2. [Google Scholar] [PubMed] [CrossRef]

4. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709. doi:10.1002/ajh.25792. [Google Scholar] [PubMed] [CrossRef]

5. Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398–406. doi:10.1038/leu.2017.253. [Google Scholar] [PubMed] [CrossRef]

6. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27. doi:10.1056/nejmoa1609324. [Google Scholar] [PubMed] [CrossRef]

7. Hehlmann R. Chronic myeloid leukemia in 2020. HemaSphere. 2020;4(5):e468. doi:10.1097/HS9.0000000000000468. [Google Scholar] [PubMed] [CrossRef]

8. Kumar V, Jyotirmayee, Verma M. Developing therapeutic approaches for chronic myeloid leukemia: a review. Mol Cell Biochem. 2023;478(5):1013–29. doi:10.1007/s11010-022-04576-0. [Google Scholar] [PubMed] [CrossRef]

9. Laganà A, Scalzulli E, Bisegna ML, Ielo C, Martelli M, Breccia M. Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Expert Rev Hematol. 2025;18(1):65–79. doi:10.1080/17474086.2024.2440776. [Google Scholar] [PubMed] [CrossRef]

10. Poudel G, Tolland MG, Hughes TP, Pagani IS. Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia. Cancers. 2022;14(14):3300. doi:10.3390/cancers14143300. [Google Scholar] [PubMed] [CrossRef]

11. Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17(1):49. doi:10.1186/s12943-018-0780-6. [Google Scholar] [PubMed] [CrossRef]

12. Parker WT, Yeung DTO, Yeoman AL, Altamura HK, Jamison BA, Field CR, et al. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood. 2016;127(15):1870–80. doi:10.1182/blood-2015-09-666214. [Google Scholar] [PubMed] [CrossRef]

13. Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013;121(3):489–98. doi:10.1182/blood-2012-05-431379. [Google Scholar] [PubMed] [CrossRef]

14. de Lavallade H, Kizilors A. The importance of mutational analysis in chronic myeloid leukaemia for treatment choice. Eur Med J Oncol. 2016;4(1):86–95. doi:10.33590/emjoncol/10311536. [Google Scholar] [CrossRef]

15. Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, et al. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol. 2012;87(11):1–4. doi:10.1002/ajh.23338. [Google Scholar] [PubMed] [CrossRef]

16. Kantarjian H, Zhai Y, Oehler VG, Jamy O, Koller PB, Haddad FG, et al. Olverembatinib in chronic myeloid leukemia—review of historical development, current status, and future research. Cancer. 2025;131(8):e35832. doi:10.1002/cncr.35832. [Google Scholar] [PubMed] [CrossRef]

17. Innes AJ, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, et al. Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Leukemia. 2024;38(11):2443–55. doi:10.1038/s41375-024-02411-7. [Google Scholar] [PubMed] [CrossRef]

18. Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36(4):431–43.e5. doi:10.1016/j.ccell.2019.08.004. [Google Scholar] [PubMed] [CrossRef]

19. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, et al. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018;59(6):1312–22. doi:10.1080/10428194.2017.1379076. [Google Scholar] [PubMed] [CrossRef]

20. Korfi K, Mandal A, Furney SJ, Wiseman D, Somervaille TCP, Marais R. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia. Ann Oncol. 2015;26(6):1180–7. doi:10.1093/annonc/mdv110. [Google Scholar] [PubMed] [CrossRef]

21. Choi EJ. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase. Blood Res. 2023;58(S1):S29–36. doi:10.5045/br.2023.2023017. [Google Scholar] [PubMed] [CrossRef]

22. Kim T, Tyndel MS, Kim HJ, Ahn JS, Choi SH, Park HJ, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2017;129(1):38–47. doi:10.1182/blood-2016-04-708560. [Google Scholar] [PubMed] [CrossRef]

23. Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132(9):948–61. doi:10.1182/blood-2018-02-832253. [Google Scholar] [PubMed] [CrossRef]

24. Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, et al. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica. 2019;104(12):2400–9. doi:10.3324/haematol.2018.200220. [Google Scholar] [PubMed] [CrossRef]

25. Adnan Awad S, Kankainen M, Ojala T, Koskenvesa P, Eldfors S, Ghimire B, et al. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Adv. 2020;4(3):546–59. doi:10.1182/bloodadvances.2019000943. [Google Scholar] [PubMed] [CrossRef]

26. Barnes EJ, Eide CA, Kaempf A, Bottomly D, Romine KA, Wilmot B, et al. Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia. Br J Haematol. 2023;200(3):323–8. doi:10.1111/bjh.18515. [Google Scholar] [PubMed] [CrossRef]

27. Pratiwi L, Mashudi FH, Ningtyas MC, Sutanto H, Romadhon PZ. Genetic profiling of acute and chronic leukemia via next-generation sequencing: current insights and future perspectives. Hematol Rep. 2025;17(2):18. doi:10.3390/hematolrep17020018. [Google Scholar] [PubMed] [CrossRef]

28. Adnan Awad S, Dufva O, Ianevski A, Ghimire B, Koski J, Maliniemi P, et al. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia. 2021;35(4):1087–99. doi:10.1038/s41375-020-01011-5. [Google Scholar] [PubMed] [CrossRef]

29. Bidikian A, Kantarjian H, Jabbour E, Short NJ, Patel K, Ravandi F, et al. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J. 2022;12(10):144. doi:10.1038/s41408-022-00742-1. [Google Scholar] [PubMed] [CrossRef]

30. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110–4. doi:10.1038/nature06866. [Google Scholar] [PubMed] [CrossRef]

31. Branford S, Hochhaus A, Mauro M, Minami Y, Rea D, Boquimpani De Moura Freitas CM, et al. Impact of mutations in blood cancer-related genes on clinical outcomes in chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 tyrosine kinase inhibitors (TKIs) in the ascembl trial. Blood. 2023;142(Suppl 1):449. doi:10.1182/blood-2023-187636. [Google Scholar] [CrossRef]

32. Soverini S, De Santis S, Martelli M, Monaldi C, Castagnetti F, Gugliotta G, et al. Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia. Leukemia. 2022;36(9):2250–60. doi:10.1038/s41375-022-01660-8. [Google Scholar] [PubMed] [CrossRef]

33. Mu H, Zou J, Zhang H. Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction. Hematol Transfus Cell Ther. 2024;46(Suppl 3):S79–85. doi:10.1016/j.htct.2023.12.007. [Google Scholar] [PubMed] [CrossRef]

34. Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009;16(2):122–31. doi:10.1177/107327480901600204. [Google Scholar] [PubMed] [CrossRef]

35. Özgür Yurttaş N, Eşkazan AE. Novel therapeutic approaches in chronic myeloid leukemia. Leuk Res. 2020;91(2):106337. doi:10.1016/j.leukres.2020.106337. [Google Scholar] [PubMed] [CrossRef]

36. Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A, Fekete S, et al. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients. Acta Haematol. 2012;127(1):34–42. doi:10.1159/000331472. [Google Scholar] [PubMed] [CrossRef]

37. Jiang Z, Gu Z, Yu X, Cheng T, Liu B. Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Front Oncol. 2024;14:1447678. doi:10.3389/fonc.2024.1447678. [Google Scholar] [PubMed] [CrossRef]

38. Hu L, Shi W, Liu K, Ma D, Xin Q, Wang Z, et al. EGFR bypass activation mediates acquired resistance to regorafenib in hepatocellular carcinoma. Front Med. 2024;11:1464610. doi:10.3389/fmed.2024.1464610. [Google Scholar] [PubMed] [CrossRef]

39. Tsubaki M, Takeda T, Noguchi M, Jinushi M, Seki S, Morii Y, et al. Overactivation of Akt contributes to MEK inhibitor primary and acquired resistance in colorectal cancer cells. Cancers. 2019;11(12):1866. doi:10.3390/cancers11121866. [Google Scholar] [PubMed] [CrossRef]

40. Larroquette M, Lefort F, Heraudet L, Bernhard JC, Ravaud A, Domblides C, et al. Therapeutic management of metastatic clear cell renal cell carcinoma: a revolution in every decade. Cancers. 2022;14(24):6230. doi:10.3390/cancers14246230. [Google Scholar] [PubMed] [CrossRef]

41. Chorzalska A, Ahsan N, Rao RSP, Roder K, Yu X, Morgan J, et al. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia. Mol Oncol. 2018;12(5):630–47. doi:10.1002/1878-0261.12186. [Google Scholar] [PubMed] [CrossRef]

42. Tsubaki M, Takeda T, Koumoto Y, Usami T, Matsuda T, Seki S, et al. Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells. Cell Prolif. 2023;56(6):e13420. doi:10.1111/cpr.13420. [Google Scholar] [PubMed] [CrossRef]

43. Tsubaki M, Takeda T, Kino T, Sakai K, Itoh T, Imano M, et al. Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells. Oncotarget. 2017;8(24):38717–30. doi:10.18632/oncotarget.16314. [Google Scholar] [PubMed] [CrossRef]

44. Tsubaki M, Takeda T, Matsuda T, Kimura A, Tanaka R, Nagayoshi S, et al. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells. BMB Rep. 2023;56(2):78–83. doi:10.5483/BMBRep.2022-0095. [Google Scholar] [PubMed] [CrossRef]

45. Cerny-Reiterer S, Ghanim V, Hoermann G, Aichberger KJ, Herrmann H, Muellauer L, et al. Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression. Neoplasia. 2012;14(7):572–84. doi:10.1593/neo.12724. [Google Scholar] [PubMed] [CrossRef]

46. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia. 2005;19(10):1774–82. doi:10.1038/sj.leu.2403898. [Google Scholar] [PubMed] [CrossRef]

47. Patterson SD, Copland M. The bone marrow immune microenvironment in CML: treatment responses, treatment-free remission, and therapeutic vulnerabilities. Curr Hematol Malig Rep. 2023;18(2):19–32. doi:10.1007/s11899-023-00688-6. [Google Scholar] [PubMed] [CrossRef]

48. Eiring AM, Kraft IL, Page BD, O’Hare T, Gunning PT, Deininger MW. STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia. Leuk Suppl. 2014;3(Suppl 1):S5–6. doi:10.1038/leusup.2014.3. [Google Scholar] [PubMed] [CrossRef]

49. Sayed D, Badrawy H, Gaber N, Khalaf MR. p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy. Leuk Res. 2014;38(2):243–50. doi:10.1016/j.leukres.2013.11.012. [Google Scholar] [PubMed] [CrossRef]

50. Shin JE, Kim SH, Kong M, Kim HR, Yoon S, Kee KM, et al. Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia. Mol Cancer. 2023;22(1):177. doi:10.1186/s12943-023-01837-4. [Google Scholar] [PubMed] [CrossRef]

51. Grockowiak E, Laperrousaz B, Jeanpierre S, Voeltzel T, Guyot B, Gobert S, et al. Immature CML cells implement a BMP autocrine loop to escape TKI treatment. Blood. 2017;130(26):2860–71. doi:10.1182/blood-2017-08-801019. [Google Scholar] [PubMed] [CrossRef]

52. Toofan P, Busch C, Morrison H, O’Brien S, Jørgensen H, Copland M, et al. Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal. Cell Death Dis. 2018;9(9):927. doi:10.1038/s41419-018-0905-2. [Google Scholar] [PubMed] [CrossRef]

53. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63. doi:10.1038/nrm3722. [Google Scholar] [PubMed] [CrossRef]

54. Ng KP, Hillmer AM, Chuah CTH, Juan WC, Ko TK, Teo ASM, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18(4):521–8. doi:10.1038/nm.2713. [Google Scholar] [PubMed] [CrossRef]

55. Zhang X, Yang Y, Yang Y, Chen H, Tu H, Li J. Exosomes from bone marrow microenvironment-derived mesenchymal stem cells affect CML cells growth and promote drug resistance to tyrosine kinase inhibitors. Stem Cells Int. 2020;2020(1):8890201. doi:10.1155/2020/8890201. [Google Scholar] [PubMed] [CrossRef]

56. Chandran RK, Geetha N, Sakthivel KM, Kumar RS, Krishna KMNJ, Sreedharan H. Differential gene expression changes and their implication on the disease progression in patients with chronic myeloid leukemia. Blood Cells Mol Dis. 2019;77(2):51–60. doi:10.1016/j.bcmd.2019.03.004. [Google Scholar] [PubMed] [CrossRef]

57. Lewis M, Prouzet-Mauléon V, Lichou F, Richard E, Iggo R, Turcq B, et al. A genome-scale CRISPR knock-out screen in chronic myeloid leukemia identifies novel drug resistance mechanisms along with intrinsic apoptosis and MAPK signaling. Cancer Med. 2020;9(18):6739–51. doi:10.1002/cam4.3231. [Google Scholar] [PubMed] [CrossRef]

58. Wang P, Wang F. Efficacy analysis of targeted P53 therapy in solid tumors. Med Oncol. 2025;42(8):360. doi:10.1007/s12032-025-02930-y. [Google Scholar] [PubMed] [CrossRef]

59. Karnwal A, Dutta J, Aqueel-Ur-Rehman, Al-Tawaha ARMS, Nesterova N. Genetic landscape of cancer: mechanisms, key genes, and therapeutic implications. Clin Transl Oncol. 2025;2025(1):1–22. doi:10.1007/s12094-025-04019-4. [Google Scholar] [PubMed] [CrossRef]

60. Lan B, Zhao N, Du K, Leng B. Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: an updated systematic review and meta-analysis. Oncol Lett. 2022;24(5):384. doi:10.3892/ol.2022.13504. [Google Scholar] [PubMed] [CrossRef]

61. Dell’Atti L, Bianchi N, Aguiari G. New therapeutic interventions for kidney carcinoma: looking to the future. Cancers. 2022;14(15):3616. doi:10.3390/cancers14153616. [Google Scholar] [PubMed] [CrossRef]

62. Jeong M, Kim KB. Recent research on role of p53 family in small-cell lung cancer. Cancers. 2025;17(7):1110. doi:10.3390/cancers17071110. [Google Scholar] [PubMed] [CrossRef]

63. Singh SR, Bhaskar R, Ghosh S, Yarlagadda B, Singh KK, Verma P, et al. Exploring the genetic orchestra of cancer: the interplay between oncogenes and tumor-suppressor genes. Cancers. 2025;17(7):1082. doi:10.3390/cancers17071082. [Google Scholar] [PubMed] [CrossRef]

64. Tuval A, Strandgren C, Heldin A, Palomar-Siles M, Wiman KG. Pharmacological reactivation of p53 in the era of precision anticancer medicine. Nat Rev Clin Oncol. 2024;21(2):106–20. doi:10.1038/s41571-023-00842-2. [Google Scholar] [PubMed] [CrossRef]

65. Kimura A, Tsubaki M, Obana T, Matsuo T, Komori R, Nagai N, et al. MDM2 inhibitors induce apoptosis by suppressing MDM2 and enhancing p53, Bax, Puma and Noxa expression levels in imatinib-resistant chronic myeloid leukemia cells. Biomed Rep. 2025;22(4):65. doi:10.3892/br.2025.1943. [Google Scholar] [PubMed] [CrossRef]

66. Carter BZ, Mak PY, Mu H, Wang X, Tao W, Mak DH, et al. Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model. Haematologica. 2020;105(5):1274–84. doi:10.3324/haematol.2019.219261. [Google Scholar] [PubMed] [CrossRef]

67. Fontecha MB, Del Rosario Anadón M, Lahitou IMM, Weich N, Bengió R, Moiraghi B, et al. Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia. Leuk Res. 2025;149:107644. doi:10.1016/j.leukres.2025.107644. [Google Scholar] [PubMed] [CrossRef]

68. Wu A, Chen M, Phoa A, Yang Z, Forrest DL, Jiang X. Identification of a PAK6-mediated MDM2/p21 axis that modulates survival and cell cycle control of drug-resistant stem/progenitor cells in chronic myeloid leukemia. Int J Mol Sci. 2025;26(13):6533. doi:10.3390/ijms26136533. [Google Scholar] [PubMed] [CrossRef]

69. Hasanova A, Asadov C, Shirinova A, Aliyeva G, Alimirzoyeva Z. Role of genetic factors in imatinib resistance of chronic myeloid leukemia: P53, RB1, ASS1 gene deletions, and chromosome 8 hyperdiploidy. Pathol Res Pract. 2025;269(10):155943. doi:10.1016/j.prp.2025.155943. [Google Scholar] [PubMed] [CrossRef]

70. Mansouri R, Heydarpour F, Yari K, Naseroleslami M, Payandeh M. Study of the association between HDAC8, SIRT1, and P53 gene expression with drug resistance in chronic myeloid leukemia patients. BMC Cancer. 2025;25(1):1665. doi:10.1186/s12885-025-15070-3. [Google Scholar] [PubMed] [CrossRef]

71. Abdulmawjood B, Costa B, Roma-Rodrigues C, Baptista PV, Fernandes AR. Genetic biomarkers in chronic myeloid leukemia: what have we learned so far? Int J Mol Sci. 2021;22(22):12516. doi:10.3390/ijms222212516. [Google Scholar] [PubMed] [CrossRef]

72. Záčková M, Moučková D, Lopotová T, Ondráčková Z, Klamová H, Moravcová J. Hsp90—a potential prognostic marker in CML. Blood Cells Mol Dis. 2013;50(3):184–9. doi:10.1016/j.bcmd.2012.11.002. [Google Scholar] [PubMed] [CrossRef]

73. Ju HQ, Wang SX, Xiang YF, Liu Z, Liu JY, Chen ZP, et al. BJ-B11, a novel Hsp90 inhibitor, induces apoptosis in human chronic myeloid leukemia K562 cells through the mitochondria-dependent pathway. Eur J Pharmacol. 2011;666(1–3):26–34. doi:10.1016/j.ejphar.2011.05.020. [Google Scholar] [PubMed] [CrossRef]

74. Tsubaki M, Matsuo T, Komori R, Nagai N, Yamamoto T, Nishida S. HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells. Future J Pharm Sci. 2025;11(1):15. doi:10.1186/s43094-025-00767-w. [Google Scholar] [CrossRef]

75. Cabaud-Gibouin V, Durand M, Quéré R, Girodon F, Garrido C, Jego G. Heat-shock proteins in leukemia and lymphoma: multitargets for innovative therapeutic approaches. Cancers. 2023;15(3):984. doi:10.3390/cancers15030984. [Google Scholar] [PubMed] [CrossRef]

76. Balatti V, Croce CM. Small non-coding RNAs in leukemia. Cancers. 2022;14(3):509. doi:10.3390/cancers14030509. [Google Scholar] [PubMed] [CrossRef]

77. Campos-Parra AD, Sánchez-Marín D, Acevedo-Sánchez V. microRNAs as sensitizers of tyrosine kinase inhibitor resistance in cancer: small molecule partnerships. Pharmaceuticals. 2025;18(4):492. doi:10.3390/ph18040492. [Google Scholar] [PubMed] [CrossRef]

78. Navabi A, Akbari B, Abdalsamadi M, Naseri S. The role of microRNAs in the development, progression and drug resistance of chronic myeloid leukemia and their potential clinical significance. Life Sci. 2022;296(17):120437. doi:10.1016/j.lfs.2022.120437. [Google Scholar] [PubMed] [CrossRef]

79. Han YC, Park CY, Bhagat G, Zhang J, Wang Y, Fan JB, et al. microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med. 2010;207(3):475–89. doi:10.1084/jem.20090831. [Google Scholar] [PubMed] [CrossRef]

80. Salati S, Salvestrini V, Carretta C, Genovese E, Rontauroli S, Zini R, et al. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget. 2017;8(30):49451–69. doi:10.18632/oncotarget.17706. [Google Scholar] [PubMed] [CrossRef]

81. Tsubaki M, Obana T, Matsuo T, Komori R, Takeda T, Koumoto Y, et al. Overexpression of miR-29a and miR-29b is involved in imatinib resistance via abrogated NF1 expression and increased ERK1/2 activation in chronic myeloid leukemia cells. Med Oncol. 2025;42(7):268. doi:10.1007/s12032-025-02838-7. [Google Scholar] [PubMed] [CrossRef]

82. Bansal M, Ansari S, Verma M. Role of miRNAs to control the progression of chronic myeloid leukemia by their expression levels. Med Oncol. 2024;41(2):55. doi:10.1007/s12032-023-02278-1. [Google Scholar] [PubMed] [CrossRef]

83. Zimmerman EI, Dollins CM, Crawford M, Grant S, Nana-Sinkam SP, Richards KL, et al. Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Mol Pharmacol. 2010;78(5):811–7. doi:10.1124/mol.110.066258. [Google Scholar] [PubMed] [CrossRef]

84. San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L, et al. microRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009;8(1):69. doi:10.1186/1476-4598-8-69. [Google Scholar] [PubMed] [CrossRef]

85. Bansal M, Verma M. Potential therapeutic targets in chronic myeloid leukemia. Med Oncol. 2025;42(8):344. doi:10.1007/s12032-025-02895-y. [Google Scholar] [PubMed] [CrossRef]

86. Shelton DN, Bhagavatula P, Sepulveda N, Beppu L, Gandhi S, Qin D, et al. Performance characteristics of the first food and drug administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia. PLoS One. 2022;17(3):e0265278. doi:10.1371/journal.pone.0265278. [Google Scholar] [PubMed] [CrossRef]

87. Curik N, Laznicka A, Krizkova J, Suchankova P, Vavrova A, Polivkova V, et al. Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia. Leukemia. 2025;39(10):2555–8. doi:10.1038/s41375-025-02732-1. [Google Scholar] [PubMed] [CrossRef]

88. Batar P, Mezei G, Illes A. Treatment-emergent resistance to asciminib in chronic myeloid leukemia patients due to myristoyl-binding pocket-mutant of BCR::BABL1/A337V can be effectively overcome with dasatinib treatment. Curr Oncol. 2025;32(2):97. doi:10.3390/curroncol32020097. [Google Scholar] [PubMed] [CrossRef]

89. Eide CA, Brewer D, Xie T, Schultz AR, Savage SL, Muratcioglu S, et al. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy. Cancer Cell. 2024;42(9):1486–8. doi:10.1016/j.ccell.2024.08.004. [Google Scholar] [PubMed] [CrossRef]

90. Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, et al. Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: a phase 1b randomized clinical trial. JAMA Oncol. 2025;11(1):28–35. doi:10.1001/jamaoncol.2024.5157. [Google Scholar] [PubMed] [CrossRef]

91. Cortes JE, Lang F, Rea D, Hochhaus A, Breccia M, Goh YT, et al. Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results. Leukemia. 2025;39(5):1124–34. doi:10.1038/s41375-025-02592-9. [Google Scholar] [PubMed] [CrossRef]

92. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99(11):2191–212. doi:10.1002/ajh.27443. [Google Scholar] [PubMed] [CrossRef]

93. Held N, Atallah EL. Real-world management of CML: outcomes and treatment patterns. Curr Hematol Malig Rep. 2023;18(5):167–75. doi:10.1007/s11899-023-00703-w. [Google Scholar] [PubMed] [CrossRef]

94. de Oliveira Medeiros GR, Funke VAM, Lima ACM, Mion ALV, Menezes I, Setubal DC, et al. The role of molecular or cytogenetic response as a favorable prognostic factor before hematopoietic stem cell transplantation for chronic myeloid leukemia. Transplant Cell Ther. 2024;30(6):597.e1–8. doi:10.1016/j.jtct.2024.03.020. [Google Scholar] [PubMed] [CrossRef]

95. Tavakoli S, Khalaj F, Kasaeian A, Ali Mousavi S, Mousavian AH, Arabi F, et al. Comparable outcomes of pre- versus post-tyrosine kinase inhibitor era treatment in chronic myeloid leukemia: a retrospective cohort study with long-term follow-up. Cell Transplant. 2023;32(4):1–12. doi:10.1177/09636897231163212. [Google Scholar] [PubMed] [CrossRef]

96. Niederwieser C, Kröger N. Transplantation in CML in the TKI era: who, when, and how? Hematology. 2022;2022(1):114–22. doi:10.1182/hematology.2022000329. [Google Scholar] [PubMed] [CrossRef]

97. Gallipoli P. JAK of all trades: ruxolitinib as a new therapeutic option for CML patients. Leuk Res. 2018;75:71–2. doi:10.1016/j.leukres.2018.10.010. [Google Scholar] [PubMed] [CrossRef]

98. Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, et al. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leuk Res. 2018;74:89–96. doi:10.1016/j.leukres.2018.10.002. [Google Scholar] [PubMed] [CrossRef]

99. Sweet KL, Othus M, Tantravahi SK, Radich JP, Thompson J, Mendler JH, et al. A phase 2, randomized trial of ruxolitinib in addition to BCR::ABL1 TKIs in CML patients with molecular evidence of disease (SWOG TRIAL S1712). HemaSphere. 2024;8(S1):159–60. doi:10.1182/blood.v128.22.1892.1892. [Google Scholar] [CrossRef]

100. Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature. 2015;525(7569):380–3. doi:10.1038/nature15248. [Google Scholar] [PubMed] [CrossRef]

101. Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, et al. Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study. Cancer. 2017;123(10):1791–9. doi:10.1002/cncr.30490. [Google Scholar] [PubMed] [CrossRef]

102. Dengler J, von Bubnoff N, Decker T, Peschel C, Duyster J. Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. Leukemia. 2005;19(10):1835–8. doi:10.1038/sj.leu.2403848. [Google Scholar] [PubMed] [CrossRef]

103. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004;101(9):3130–5. doi:10.1073/pnas.0400063101. [Google Scholar] [PubMed] [CrossRef]

104. Mancini M, Corradi V, Petta S, Martinelli G, Barbieri E, Santucci MA. mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leuk Res. 2010;34(5):641–8. doi:10.1016/j.leukres.2009.07.012. [Google Scholar] [PubMed] [CrossRef]

105. Kwon HJ, Shin JE, Khan A, Park SY, Kim J, Lee JY, et al. KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia. Mol Cancer. 2025;24(1):114. doi:10.1186/s12943-025-02292-z. [Google Scholar] [PubMed] [CrossRef]

106. Busch C, Mulholland T, Zagnoni M, Dalby M, Berry C, Wheadon H. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach. Cell Commun Signal. 2023;21(1):342. doi:10.1186/s12964-023-01363-2. [Google Scholar] [PubMed] [CrossRef]

107. Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013;12(3):316–28. doi:10.1016/j.stem.2012.12.011. [Google Scholar] [PubMed] [CrossRef]

108. Massimino M, Vigneri P, Stella S, Tirrò E, Pennisi MS, Parrinello LN, et al. Combined inhibition of Bcl2 and Bcr-Abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells. J Clin Med. 2021;10(23):5606. doi:10.3390/jcm10235606. [Google Scholar] [PubMed] [CrossRef]

109. Parry N, Busch C, Aßmann V, Cassels J, Hair A, Helgason GV, et al. BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia. Cell Death Discov. 2022;8(1):457. doi:10.1038/s41420-022-01211-1. [Google Scholar] [PubMed] [CrossRef]

110. Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, et al. Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias. Acta Haematol. 2021;143(6):567–73. doi:10.1159/000506346. [Google Scholar] [PubMed] [CrossRef]

111. Kurosu T, Wu N, Oshikawa G, Kagechika H, Miura O. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. Apoptosis. 2010;15(5):608–20. doi:10.1007/s10495-010-0457-0. [Google Scholar] [PubMed] [CrossRef]

112. Peterson LF, Mitrikeska E, Giannola D, Lui Y, Sun H, Bixby D, et al. p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia. 2011;25(5):761–9. doi:10.1038/leu.2011.7. [Google Scholar] [PubMed] [CrossRef]

113. Scott MT, Liu W, Mitchell R, Clarke CJ, Kinstrie R, Warren F, et al. Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease. Nat Commun. 2024;15(1):651. doi:10.1038/s41467-024-44771-9. [Google Scholar] [PubMed] [CrossRef]

114. Peng C, Brain J, Hu Y, Goodrich A, Kong L, Grayzel D, et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood. 2007;110(2):678–85. doi:10.1182/blood-2006-10-054098. [Google Scholar] [PubMed] [CrossRef]

115. Tauchi T, Okabe S, Ashihara E, Kimura S, Maekawa T, Ohyashiki K. Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen. Oncogene. 2011;30(24):2789–97. doi:10.1038/onc.2011.3. [Google Scholar] [PubMed] [CrossRef]

116. Anelli L, Zagaria A, Specchia G, Musto P, Albano F. Dysregulation of miRNA in leukemia: exploiting miRNA expression profiles as biomarkers. Int J Mol Sci. 2021;22(13):7156. doi:10.3390/ijms22137156. [Google Scholar] [PubMed] [CrossRef]

117. Keramati F, Jafarian A, Soltani A, Javandoost E, Mollaei M, Fallah P. Circulating miRNAs can serve as potential diagnostic biomarkers in chronic myelogenous leukemia patients. Leuk Res Rep. 2021;16(6):100257. doi:10.1016/j.lrr.2021.100257. [Google Scholar] [PubMed] [CrossRef]